Featured Platforms
  


Custom Protein Generation

Mammalian- Derived Products

Microbial- Derived Products

Antibody Drug Conjugates

Bispecific Ab Platform

Technologies & Platforms

We operate sites in Wuxi, Shanghai and Suzhou, China, and have new sites in development in the United States, Singapore and Ireland. Our world-class facilities in Wuxi and Shanghai adhere to global regulatory standards and comply with cGMP regulations, enabling us to simultaneously advance the development and registration of innovative biologics and biosimilars for the global market.

Shanghai, China
  • Opened October 2011
  • 17,748 sq. m. facility
  • One of the largest biologics development laboratories in the world
  • One of the first facilities in the world with an integrated platform spanning biologics drug discovery to late-phase (phase III) clinical development

facilities-02

Wuxi City, China
  • Opened October 2012
  • 15,296 sq. m. facility
  • One of the first facilities in the world to use fully disposable bioreactors
  • ISPE “Facility of the Year” Honorable Mention Award
  • cGMP compliant since its inception
 

Suzhou City, China
  • Opened December 2014
  • 10,116 sq. m. facility
  • The first non-government affiliated biosafety testing facility in Asia

Dundalk, Ireland
  • “Factory of the Future”
  • Biologics drug substance manufacturing facility
  • Site acquired April 2018
  • Operations to commence in 2021

Dundalk, Ireland
  • Adjacent to the “Factory of the Future”
  • Vaccine manufacturing facility
  • Operations to commence in 2022

Singapore
  • Site acquired May 2018

BACK